Liver Cancer
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 15, 2004; 10(4): 505-508
Published online Feb 15, 2004. doi: 10.3748/wjg.v10.i4.505
Comparison of transcatheter arterial chemoembolization, laparoscopic radiofrequency ablation, and conservative treatment for decompensated cirrhotic patients with hepatocellular carcinoma
Chung-Bao Hsieh, Hao-Ming Chang, Teng-Wei Chen, Chung-Jueng Chen, De-Chuan Chan, Jyh-Cherng Yu, Yao-Chi Liu, Tzu-Ming Chang, Kuo-Liang Shen
Chung-Bao Hsieh, Hao-Ming Chang, Teng-Wei Chen, Chung-Jueng Chen, De-Chuan Chan, Jyh-Cherng Yu, Yao-Chi Liu, Kuo-Liang Shen, Devision of General Surgery, Department of Surgery, Department of Medicine, National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan, China
Tzu-Ming Chang, Department of Surgery, Tungs’ Taichung Metroharbor Hospital, Taichung, Taiwan, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Chung-Bao Hsieh, 325, Sec 2, Cheng-Kung Road, Taipei, Taiwan, China. albert0920@yahoo.com.tw
Telephone: +886-2-87927191 Fax: +886-2-87927273
Received: November 22, 2003
Revised: December 5, 2003
Accepted: December 16, 2003
Published online: February 15, 2004
Abstract

AIM: To compare the therapeutic effect of transcatheter arterial chemoembolization (TACE), laparoscopic radiofrequency ablation (LRFA), and conservative treatment for the therapy of decompensated liver cirrhosis patients with hepatocellular carcinomas (HCC).

METHODS: Between October 2000 and July 2003, one hundred patients with histologically proven primary HCC and clinical decompensated liver cirrhosis (Child classification B or C) were included in this study. Forty patients received LRFA (LRFA group), twenty received TACE (TACE group), and forty received conservative treatment (control group). We compared the survival, recurrence, and complication rates in these three groups, making adjustment using the tumor metastastic node staging system.

RESULTS: The major complication rate in the TACE group (9/20) was significantly higher than that in the LRFA group (7/40). For patients with TMN stage II HCC, the survival rate of the LRFA group was better than that of the TACE and control groups (P = 0.003) but the recurrence rates befween the LRFA and TACE groups did not differ.

CONCLUSION: The LRFA group of patients had better clinical outcomes in terms of survival and complication rates in comparison with the TACE group or conservative treatment in patients with decompensated liver cirrhosis, especially in TMN patients with stage II HCC. LRFA is thus an appropriate alternative treatment for poor liver function among patients with HCC.

Keywords: $[Keywords]